Fluconazole plus Cyclosporine: a Fungicidal Combination Effective against Experimental Endocarditis Due to Candida albicans
暂无分享,去创建一个
[1] D. Sanglard,et al. Potent Synergism of the Combination of Fluconazole and Cyclosporine in Candida albicans , 2000, Antimicrobial Agents and Chemotherapy.
[2] Joseph Heitman,et al. Synergistic Antifungal Activities of Bafilomycin A1, Fluconazole, and the Pneumocandin MK-0991/Caspofungin Acetate (L-743,873) with Calcineurin Inhibitors FK506 and L-685,818 against Cryptococcus neoformans , 2000, Antimicrobial Agents and Chemotherapy.
[3] Michael H. Miller,et al. Pharmacokinetic Studies of Fluconazole in Rabbits Characterizing Doses Which Achieve Peak Levels in Serum and Area under the Concentration-Time Curve Values Which Mimic Those of High-Dose Fluconazole in Humans , 1998, Antimicrobial Agents and Chemotherapy.
[4] K. Kuchler,et al. Genetic separation of FK506 susceptibility and drug transport in the yeast Pdr5 ATP-binding cassette multidrug resistance transporter. , 1998, Molecular biology of the cell.
[5] R. Chen,et al. Effectiveness of quinolone antibiotics in modulating the effects of antifungal drugs , 1997, Antimicrobial agents and chemotherapy.
[6] K. Joiner,et al. Characterization of anti-Toxoplasma activity of SDZ 215-918, a cyclosporin derivative lacking immunosuppressive and peptidyl-prolyl-isomerase-inhibiting activity: possible role of a P glycoprotein in Toxoplasma physiology , 1997, Antimicrobial agents and chemotherapy.
[7] M. Ghannoum,et al. Combination therapy with amphotericin B and fluconazole against invasive candidiasis in neutropenic-mouse and infective-endocarditis rabbit models , 1997, Antimicrobial agents and chemotherapy.
[8] D. Sanglard,et al. Cloning of Candida albicans genes conferring resistance to azole antifungal agents: characterization of CDR2, a new multidrug ABC transporter gene. , 1997, Microbiology.
[9] E. Anaissie,et al. Controversies in management of candidiasis in neutropenic patients treated for malignant diseases: new versus old or better versus worse , 1997 .
[10] D. Sanglard,et al. Susceptibilities of Candida albicans multidrug transporter mutants to various antifungal agents and other metabolic inhibitors , 1996, Antimicrobial agents and chemotherapy.
[11] L Timmermann,et al. The mechanism of action of cyclosporin A and FK506. , 1996, Clinical immunology and immunopathology.
[12] D. Snydman,et al. The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. , 1996, The American journal of medicine.
[13] A. List,et al. Role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia. , 1996, Leukemia.
[14] R. Farinotti,et al. Comparison of fluconazole and amphotericin B for treatment of experimental Candida albicans endocarditis in rabbits , 1996, Antimicrobial agents and chemotherapy.
[15] E. Brummer,et al. Synergy of fluconazole with human monocytes or monocyte-derived macrophages for killing of Candida species. , 1995, The Journal of infectious diseases.
[16] K. Kuchler,et al. Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters , 1995, Antimicrobial agents and chemotherapy.
[17] E. Anaissie,et al. Safety, plasma concentrations, and efficacy of high-dose fluconazole in invasive mold infections. , 1995, The Journal of infectious diseases.
[18] M. Levenstein,et al. A Randomized Trial Comparing Fluconazole with Amphotericin B for the Treatment of Candidemia in Patients without Neutropenia , 1994 .
[19] A. Bayer,et al. Comparison of fluconazole and amphotericin B for treatment of experimental Candida endocarditis caused by non-C. albicans strains , 1993, Antimicrobial Agents and Chemotherapy.
[20] D. Irwin,et al. Isogenic strain construction and gene mapping in Candida albicans. , 1993, Genetics.
[21] C. Beck-Sague,et al. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System. , 1993, The Journal of infectious diseases.
[22] C. Higgins,et al. ABC transporters: from microorganisms to man. , 1992, Annual review of cell biology.
[23] C. Klee,et al. Calcineurin phosphatase activity in T lymphocytes is inhibited by FK 506 and cyclosporin A. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[24] K. A. Porter,et al. The Kidneys: The Urinary Tract , 1992 .
[25] S. Schreiber,et al. The mechanism of action of cyclosporin A and FK506. , 1992, Immunology today.
[26] M. Witt,et al. Comparison of fluconazole and amphotericin B for prevention and treatment of experimental Candida endocarditis , 1991, Antimicrobial Agents and Chemotherapy.
[27] Stuart L. Schreiber,et al. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes , 1991, Cell.
[28] P. Sonneveld,et al. Reversal of drug‐resistance by cyclosporin‐A in a patient with acute myelocytic leukaemia , 1990, British journal of haematology.
[29] J. K. Faulkner,et al. Pharmacokinetics and tissue penetration of fluconazole in humans. , 1990, Reviews of infectious diseases.
[30] H. Gallis,et al. Amphotericin B: 30 years of clinical experience. , 1990, Reviews of infectious diseases.
[31] A. Schaffner,et al. Comparison of immunosuppressive effects of cyclosporine A in a murine model of systemic candidiasis and of localized thrushlike lesions , 1989, Infection and immunity.
[32] T. Walsh,et al. Pharmacokinetics and tissue penetration of fluconazole in rabbits , 1989, Antimicrobial Agents and Chemotherapy.
[33] C. Mody,et al. Treatment of murine cryptococcosis with cyclosporin-A in normal and athymic mice. , 1989, The American review of respiratory disease.
[34] I. Pastan,et al. Multiple-drug resistance in human cancer. , 1987, The New England journal of medicine.
[35] S. Thiru,et al. BLOOD LEVELS AND NEPHROTOXICITY OF CYCLOSPORIN A AND G IN RATS , 1986, The Lancet.
[36] J. Perfect,et al. Comparison of amphotericin B and N-D-ornithyl amphotericin B methyl ester in experimental cryptococcal meningitis and Candida albicans endocarditis with pyelonephritis , 1985, Antimicrobial Agents and Chemotherapy.
[37] M. Haynes,et al. Cyclosporin partitions into phospholipid vesicles and disrupts membrane architecture. , 1985, Immunology letters.
[38] J. Fierer,et al. Cyclosporin A inhibits Coccidioides immitis in vitro and in vivo , 1983, Antimicrobial Agents and Chemotherapy.
[39] M. Glauser,et al. Natural history of aortic valve endocarditis in rats , 1982, Infection and immunity.
[40] M. Rotondo,et al. Candida albicans Endocarditis: Ultrastructural Studies of Vegetation Formation , 1978, Infection and immunity.
[41] J. Rahal,et al. Tissue penetration of amphotericin B in Candida endocarditis. , 1974, Chest.
[42] B. T. Fields,et al. Amphotericin B serum concentrations during therapy. , 1970, Applied microbiology.